About Freeox Biotech
Freeox Biotech is a Healthcare company based in Barcelona (Spain) founded in 2017 by Angel Honrado and Carlos Lurigados. Therapies for ischaemic stroke treatment are being developed. Freeox Biotech has raised $572.84 thousand across 2 funding rounds from investors including EIT Health, Montserrat Esteve and Francisco Javier Pérez Gracia. Its chief executive, as recorded, is Carlos Lurigados. Freeox Biotech offers products and services including Ox-01 and Lip-Ox. Its focus areas include Life Sciences, Neurology, Drugs and Neural Injury.
Company details
Freeox Biotech was founded in 2017 in Barcelona, Spain, within the biotechnology sector. Therapies targeting neurological and cardiovascular disorders are developed, with a focus on ischaemic stroke. The lead candidate, Ox-01 based on uric acid, offers neuroprotection against reperfusion injury and supports extracellular SOD3 to maintain vascular function. Phase IIb clinical trials for this product have been completed.
- Headquarters Barcelona, Spain
- Founders Angel Honrado, Carlos Lurigados
- SectorsHealthcare
- Email••••••••
- Website freeoxbiotech.com
- Social LinkedIn X
- Total Equity Funding$572.84K (USD)
in 2 rounds
- Latest Funding Round$572.84K (USD), Angel Round
Nov 2018
- InvestorsEIT Health
& 2 more
Products & Services of Freeox Biotech
Freeox Biotech offers a comprehensive portfolio of products and services, including Ox-01 and Lip-Ox.
Phase III-ready drug for cerebrovascular protection and therapy.
Proprietary liposomal system based on uric acid for drug development.
Funding Insights of Freeox Biotech
Freeox Biotech has successfully raised a total of $572.84K across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $572.84 thousand completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $572,841
- Total Rounds 2
- Last Round Angel Round — $572,841
- First Round $34,814
(Aug 2018)
- Investors Count 3
All 2 funding rounds of Freeox Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $572,841 | Angel Round | – | – | |
| Aug 2018 | $34,814 | Grant | – | – |
3 investors in total: 1 institutional and 2 angel.
Investors in Freeox Biotech
Freeox Biotech has secured backing from 3 investors, including angel and venture fund investors. Prominent investors backing the company include EIT Health, Montserrat Esteve and Francisco Javier Pérez Gracia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare startups are accelerated and incubated through specialized programs. | 2015 | eithealth.eu | Munich, Germany | |
ME Montserrat Esteve | unknown_69630444f8fe4f43b | |||
FJ Francisco Javier Pérez Gracia | unknown_0ca28c8bae1641889 |
Investor details for Freeox Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Freeox Biotech
6 people are tracked at Freeox Biotech (3 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Angel Honrado | Co-Founder | Leadership |
Carlos Lurigados | Co-Founder & CEO | Leadership |
Julián Peña | Interim CFO | Leadership |
Tudor G. Jovin | Advisor | Board & advisors |
Joan Bigorra | Advisor | Board & advisors |
Ángel Chamorro | Advisor | Board & advisors |
Complete people profiles for Freeox Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Freeox Biotech
3 dated milestones of Freeox Biotech across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Freeox Biotech is founded.
- Funding First funding round of $35K.
- Funding Latest funding round, Angel Round, of $573K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Freeox Biotech
Complete news archive for Freeox Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Freeox Biotech
Freeox Biotech was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Freeox Biotech is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Carlos Lurigados is the CEO of Freeox Biotech, as recorded in our data. They have also founded this company.
Freeox Biotech is a funded company, having raised a total of $572.84K across 2 funding rounds to date. The company's 1st funding round was a Grant of $34.81K, raised on Aug 2018.
Freeox Biotech was founded in 2017 in Barcelona, Spain, within the biotechnology sector. Therapies targeting neurological and cardiovascular disorders are developed, with a focus on ischaemic stroke. The lead candidate, Ox-01 based on uric acid, offers neuroprotection against reperfusion injury and supports extracellular SOD3 to maintain vascular function. Phase IIb clinical trials for this product have been completed.
Freeox Biotech offers Ox-01 and Lip-Ox.
Freeox Biotech has 3 investors. Key investors include EIT Health, Montserrat Esteve, and Francisco Javier Pérez Gracia.